Ohl, 2,344 patient remdesivir late treatment PSM study: 6% higher mortality [p=0.66] and 100% longer hospitalization [p=0.001] https://c19p.org/ohl
copied to clipboard
Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19
et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.14741
Retrospective 5,898 hospitalized patients in the USA, 2,374 receiving remdesivir treatment, showing no significant difference in mortality, and a longer time to hospital discharge with treatment.[Gérard, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
|
risk of death, 6.0% higher, HR 1.06, p = 0.66, treatment 143 of 1,172 (12.2%), control 124 of 1,172 (10.6%), adjusted per study, PSM, Cox proportional hazards regression.
|
|
hospitalization time, 100% higher, relative time 2.00, p < 0.001, treatment 1,172, control 1,172, PSM, Cox proportional hazards regression.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Ohl et al., 7/15/2021, retrospective, propensity score matching, USA, North America, peer-reviewed, 9 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.